Poor
Misaligned
Patient Risk:
High
Summary
Several statements are unsupported or go beyond the provided FDA label excerpts (e.g., specific antidepressant interaction claims, serotonin/brain effects, REDUCE-IT “no antidepressant interactions,” antidepressant-linked bleeding-risk claims, grapefruit/alcohol effects, bipolar/mania risks). Major on-label claims about indications and bleeding/antiplatelet risk are not addressed directly in the response, leaving substantial misalignment with the supplied prescribing information.
Category Scores
Accurate Statements
Vascepa mildly increases bleeding time.
7.1 Increased Bleeding Risk with Anticoagulants and Antiplatelet Agents: prolongation of bleeding time observed in some published studies; not exceeded normal limits; did not produce clinically significant bleeding episodes.
Vascepa has antiplatelet effects.
12.1 Mechanism of Action: EPA inhibits platelet aggregation under some ex vivo conditions.
A causal relationship between Vascepa and mood changes has not been established.
Not supported or contradicted by the provided label excerpts (no statement about mood changes/causality in provided sections); therefore this cannot be counted as accurate support.
Unsupported Statements
Vascepa (icosapent ethyl) is used to lower triglycerides.
The provided label excerpt supports TG lowering only as an indication context: 'adjunct to diet to reduce TG levels' or 'adjunct to maximally tolerated statin therapy...' The statement is too general and omits the labeled indication qualifiers.
No major pharmacokinetic interactions have been reported between Vascepa and antidepressants such as SSRIs (e.g., sertraline, fluoxetine).
7 DRUG INTERACTIONS section excerpt provided does not include antidepressants or any claim about pharmacokinetic interactions with antidepressants.
No major pharmacokinetic interactions have been reported between Vascepa and antidepressants such as SNRIs (e.g., venlafaxine, duloxetine).
Not supported by provided label excerpt.
No major pharmacokinetic interactions have been reported between Vascepa and antidepressants such as bupropion.
Not supported by provided label excerpt.
No major pharmacokinetic interactions have been reported between Vascepa and antidepressants such as mirtazapine.
Not supported by provided label excerpt.
Vascepa does not inhibit CYP450 enzymes.
No such CYP450 inhibition/induction statement is included in the provided label excerpts.
Vascepa does not induce CYP450 enzymes.
No such CYP450 inhibition/induction statement is included in the provided label excerpts.
Most antidepressants are metabolized by CYP450 enzymes.
Not addressed in provided label excerpts.
Blood levels of antidepressant drugs remain unaffected by Vascepa.
Not addressed in provided label excerpts.
Patients on Vascepa sometimes report mood changes, including new or worsening depression.
Not supported by provided label excerpts; label excerpt includes adverse reactions but does not mention depression/mood changes.
Omega-3s like EPA can influence brain inflammation and serotonin pathways.
Not addressed in provided label excerpts.
Omega-3s like EPA may augment antidepressant effects in some studies.
Not addressed in provided label excerpts.
Clinical trials for Vascepa focused on cardiovascular outcomes rather than mental health.
While REDUCE-IT is described as cardiovascular outcomes in the provided excerpts, the claim about mental health focus is not explicitly supported.
No direct synergy or antagonism with antidepressants is documented for Vascepa.
Not addressed in provided label excerpts.
Combining Vascepa with SSRIs may increase bruising, nosebleeds, or GI bleeding.
Provided label excerpt only discusses increased bleeding risk with anticoagulants/antiplatelet agents generally, not SSRIs specifically or specific bleeding manifestations.
The increased bleeding risk with Vascepa and SSRIs may be especially relevant when aspirin or anticoagulants are also used.
Label excerpt mentions incidence of bleeding greater with concomitant antithrombotic medications such as aspirin/clopidogrel/warfarin, but it does not make an SSRIs-specific interaction or statement tied to SSRIs.
Unusual bleeding should be monitored for when using Vascepa with SSRIs and other agents that increase bleeding risk.
Label excerpt instructs to monitor patients receiving VASCEPA with concomitant anticoagulants and/or antiplatelet agents; it does not mention SSRIs.
No dose adjustments are routinely needed when combining Vascepa with SSRIs.
Provided label excerpt does not mention SSRIs or dosing adjustments.
Many Vascepa users take statins.
Not stated in provided label excerpts (e.g., REDUCE-IT includes statin-treated adults, but the general statement about 'many users' is not supported).
Statins have no interactions with antidepressants.
Not addressed in provided label excerpts.
Vascepa avoids grapefruit juice issues, unlike some statins.
No grapefruit juice or statin-grapefruit discussion is included in provided label excerpts.
Grapefruit juice issues may be a concern for drugs like sertraline.
Not addressed in provided label excerpts.
Alcohol may amplify Vascepa's GI side effects.
Not addressed in provided label excerpts.
Alcohol amplifies Vascepa's GI side effects not via antidepressants.
Not addressed in provided label excerpts.
The REDUCE-IT trial showed no antidepressant interactions with Vascepa.
Not supported by provided label excerpts. Provided excerpt does not discuss antidepressant coadministration/interactions.
Real-world data from FDA reports note rare mood complaints with Vascepa.
Not addressed in provided label excerpts.
Rare mood complaints with Vascepa occur in under 1% of cases.
Not addressed in provided label excerpts.
Rare mood complaints with Vascepa were not linked to specific antidepressants.
Not addressed in provided label excerpts.
Omega-3s might trigger mania in patients with bipolar disorder.
Not addressed in provided label excerpts.
In patients with bipolar disorder, personalized risks with Vascepa are advised by consulting a doctor.
Not addressed in provided label excerpts.
Contradictions
Important Omissions
Approved indication details from the label (adjunct to maximally tolerated statin therapy to reduce risk of MI/stroke/coronary revascularization/unstable angina hospitalization in adults with TG ≥150 mg/dL and established CVD or diabetes plus risk factors; adjunct to diet to reduce TG in severe hypertriglyceridemia ≥500 mg/dL).
Importance:
High
Label dosage and administration (4 g/day as 0.5 g BID x4 capsules or 1 g BID x2 capsules with food; swallow whole; do not break open/crush/dissolve/chew).
Importance:
High
Contraindications (hypersensitivity to VASCEPA or components).
Importance:
Moderate
Key warnings/precautions relevant to safety monitoring: atrial fibrillation/flutter risk and bleeding risk (including greater incidence with concomitant antithrombotics such as aspirin/clopidogrel/warfarin) and associated monitoring as stated.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes numerous unsupported claims about antidepressant pharmacokinetics/interactions, mood/depression, serotonin pathways, grapefruit/alcohol effects, bipolar/mania, and specific bleeding-risk assumptions with SSRIs. It omits key label elements for indications, dosing, contraindications, and core warnings (atrial fibrillation/flutter and bleeding with antithrombotics) necessary for safe, on-label use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Misaligned
Primary Issue
Major portions of the response are unsupported by the provided FDA prescribing information and introduce multiple claims (antidepressant interactions, CNS/serotonin effects, mood/depression and bipolar/mania, grapefruit/alcohol effects, SSRIs-specific bleeding increases, and REDUCE-IT antidepressant interaction conclusions) that are not present in the label excerpts.
Suggested Improvement
Restrict claims to what is explicitly supported in the supplied label sections: approved indications, labeled dosing/admin instructions, contraindication, atrial fibrillation/flutter warning, bleeding risk with concomitant antithrombotics and monitoring, and the general mechanism/bleeding-time/platelet-aggregation statements from the provided sections. Remove or qualify all unsupported antidepressant/CNS/mood/bipolar/grapefruit/alcohol/REDUCE-IT antidepressant interaction assertions.